Compare Adaptive Biotechnologies Corp (ADPT) vs Intuitive Surgical, Inc. (ISRG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Intuitive Surgical, Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $20.12 (market cap $3.33B), while Intuitive Surgical, Inc. trades at $418.56 (market cap $151.33B). The key difference: Intuitive Surgical, Inc. is far larger — about 45.4× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Intuitive Surgical, Inc. nearer its low. Which is the better fit depends on your goals.
| ADPT | ISRG | |
|---|---|---|
Market Cap | $3.33B | $151.33B |
Sector | Health | Health |
52-Week High | $22.37 | $592.85 |
52-Week Low | $10.24 | $397.68 |
Enterprise Value | $3.19B | $146.82B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Intuitive Surgical (ISRG) trades at $427.30, up 0.3% on the day, with a bullish technical outlook supported by moving averages and strong support at $422. The company reported robust Q1 2026 earnings of $2.50 per share, beating estimates, and has consistently exceeded expectations. Revenue grew to $10.06 billion in 2025, with a net income margin of 28.15%, though valuation multiples remain elevated with a P/E of 52.59.
The outlook is positive, driven by procedure growth guidance of 13.5-15.5% for 2026 and analyst consensus targeting $565.20. Risks include premium valuation sensitivity and reimbursement challenges in new markets like appendectomy. Institutional sentiment is bullish, with 69% of analysts rating it a buy, but investors should monitor execution against high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →
